IVX-411
SARS-CoV-2 | |
---|---|
Vaccine type | Virus-like particles |
Clinical data | |
Routes of administration | Intramuscular |
IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
References
- ^ "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
- ^ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Retrieved 18 August 2021.
- ^ "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
- PMID 33873199.